LymphedemaLEGNCT00956670
Lymphedema After Surgery in Patients With Endometrial Cancer, Cervical Cancer, or Vulvar Cancer
A study testing Quality-of-Life Assessment, Questionnaire Administration and Study of High Risk Factors in people with Lymphedema and Stage IA Cervical Cancer, run by Gynecologic Oncology Group at 213 sites in United States.
Trial summary
This clinical trial studies lymphedema after surgery in patients with endometrial cancer, cervical cancer, or vulvar cancer. Collecting information over time about how often lymphedema occurs in patients undergoing surgery and lymphadenectomy for endometrial cancer, cervical cancer, and vulvar cancer may help doctors… Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Lymphedema, Stage IA Cervical Cancer, Stage IA Uterine Corpus Cancer
- What is being tested?
- Quality-of-Life Assessment, Questionnaire Administration and Study of High Risk Factors
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1,055 participants
- Where
- 213 sitesUnited States
- Study dates
- Jun 2012to Apr 2015
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients will be registered into three distinct groupings, and each group will be analyzed as a separate study:
- Patients who will undergo or have undergone hysterectomy/bilateral salpingo-oophorectomy (BSO) and pelvic lymphadenectomy +/- para-aortic node sampling via open or laparoscopic technique for clinical stage I-II or surgical stage I-III uterine carcinoma, including those receiving postoperative adjuvant therapy; patients enrolling after surgery may have a pathologic stage of I-III OR
- Patients who will undergo or have undergone radical hysterectomy or trachelectomy and pelvic lymphadenectomy +/- para-aortic node sampling via open or laparoscopic technique for clinical stage IA-IIA cervical carcinoma, including those receiving postoperative adjuvant therapy OR
- Patients with vulvar cancer who will undergo or have undergone definitive surgery for primary stage I-IV vulvar cancer who will or have received a radical vulvectomy or radical local excision with concurrent unilateral or bilateral inguinal or inguinal-femoral lymphadenectomy; patients who are going to receive multi-modality therapy (radiation +/-chemotherapy) after undergoing surgery are eligible; patients may undergo sentinel node mapping as long as it is followed by a full lymphadenectomy; (note: enrollment of vulvar patients was closed on June 9, 2014; no vulvar patients will be enrolled after closure of this arm)
- Patients must have signed an approved informed consent and authorization permitting release of personal health information
- Patients must have a serum albumin level of >= 3.0 within 14 days of entry
- Surgery must occur within 5 business days before study entry or within eight weeks after study entry
Who cannot join
- Patients with any prior clinical history of lower extremity lymphedema
- Patients who have a history of congestive heart failure, chronic renal disease, or chronic liver disease
- Patients with a prior history of chronic lower extremity swelling
- Patients with a Gynecologic Oncology Group (GOG) performance grade of 3 or 4
- Patients with a history of other invasive malignancies if their previous cancer treatment included any of the surgical procedures
- Patients who have had prior lower extremity vascular surgery (arterial or venous)
Show all 12Show fewer
- Patients who have had prior pelvic, abdominal, inguinal, or lower extremity radiation therapy
- Patients who have had or are going to receive another elective surgery during the same operative event as their pelvic (cervical or uterine cancers) or inguinal (vulvar) lymphadenectomy
- Vulvar patients, from June 9, 2014 on
- Patients cannot be enrolled on the trial unless there is at least one person at the participating site who has been trained in performing limb measurements
- Patients who do not undergo or have not undergone the lymphadenectomy portion of the procedure
- Patients who enter the study and then undergo sentinel node biopsy without the intention of undergoing complete lymphadenectomy
Trial locations and contacts
213 sites in 1 country.
213 sites in 1 country
United States213 sites
Abington Memorial Hospital
Abington, Pennsylvania, 19001
Summa Akron City Hospital/Cooper Cancer Center
Akron, Ohio, 44304
University of New Mexico Cancer Center
Albuquerque, New Mexico, 87102
Southwest Gynecologic Oncology Associates Inc
Albuquerque, New Mexico, 87106
AnMed Health Cancer Center
Anderson, South Carolina, 29621
Saint Joseph Mercy Hospital
Ann Arbor, Michigan, 48106-0995
Michigan Cancer Research Consortium NCORP
Ann Arbor, Michigan, 48106
Emory University Hospital Midtown
Atlanta, Georgia, 30308
Emory University/Winship Cancer Institute
Atlanta, Georgia, 30322
Sutter Auburn Faith Hospital
Auburn, California, 95602
Sutter Cancer Centers Radiation Oncology Services-Auburn
Auburn, California, 95603
Augusta University Medical Center
Augusta, Georgia, 30912
University of Colorado Cancer Center - Anschutz Cancer Pavilion
Aurora, Colorado, 80045
Hematology/Oncology Clinic LLP
Baton Rouge, Louisiana, 70809
Bronson Battle Creek
Battle Creek, Michigan, 49017
Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California, 94704
Spectrum Health Big Rapids Hospital
Big Rapids, Michigan, 49307
Billings Clinic Cancer Center
Billings, Montana, 59101
Saint Vincent Healthcare
Billings, Montana, 59101
Montana Cancer Consortium NCORP
Billings, Montana, 59102
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, 35233
Saint Alphonsus Cancer Care Center-Boise
Boise, Idaho, 83706
Bozeman Deaconess Hospital
Bozeman, Montana, 59715
State University of New York Downstate Medical Center
Brooklyn, New York, 11203
Bryn Mawr Hospital
Bryn Mawr, Pennsylvania, 19010
Mills - Peninsula Hospitals
Burlingame, California, 94010
Fairview Ridges Hospital
Burnsville, Minnesota, 55337
Saint James Community Hospital and Cancer Treatment Center
Butte, Montana, 59701
Sutter Cancer Centers Radiation Oncology Services-Cameron Park
Cameron Park, California, 95682
Rocky Mountain Oncology
Casper, Wyoming, 82609
Cancer Center of Kansas - Chanute
Chanute, Kansas, 66720
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, 27599
Novant Health Presbyterian Medical Center
Charlotte, North Carolina, 28204
Case Western Reserve University
Cleveland, Ohio, 44106
Cleveland Clinic Cancer Center/Fairview Hospital
Cleveland, Ohio, 44111
Cleveland Clinic Foundation
Cleveland, Ohio, 44195
Medical Oncology and Hematology Associates-West Des Moines
Clive, Iowa, 50325
Mercy Cancer Center-West Lakes
Clive, Iowa, 50325
John B Amos Cancer Center
Columbus, Georgia, 31904
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210
Riverside Methodist Hospital
Columbus, Ohio, 43214
Mercy Hospital
Coon Rapids, Minnesota, 55433
Parkland Memorial Hospital
Dallas, Texas, 75235
UT Southwestern/Simmons Cancer Center-Dallas
Dallas, Texas, 75390
Carle on Vermilion
Danville, Illinois, 61832
Geisinger Medical Center
Danville, Pennsylvania, 17822
Sutter Davis Hospital
Davis, California, 95616
Beaumont Hospital-Dearborn
Dearborn, Michigan, 48124
Iowa Methodist Medical Center
Des Moines, Iowa, 50309
Iowa-Wide Oncology Research Coalition NCORP
Des Moines, Iowa, 50309
Medical Oncology and Hematology Associates-Des Moines
Des Moines, Iowa, 50309
Medical Oncology and Hematology Associates-Laurel
Des Moines, Iowa, 50314
Mercy Medical Center - Des Moines
Des Moines, Iowa, 50314
Iowa Lutheran Hospital
Des Moines, Iowa, 50316
Saint John Hospital and Medical Center
Detroit, Michigan, 48236
Cancer Center of Kansas - Dodge City
Dodge City, Kansas, 67801
City of Hope Comprehensive Cancer Center
Duarte, California, 91010
Fairview-Southdale Hospital
Edina, Minnesota, 55435
Carle Physician Group-Effingham
Effingham, Illinois, 62401
Cancer Center of Kansas - El Dorado
El Dorado, Kansas, 67042
Union Hospital of Cecil County
Elkton, Maryland, 21921
Hurley Medical Center
Flint, Michigan, 48502
Genesys Hurley Cancer Institute
Flint, Michigan, 48503
Cancer Center of Kansas - Fort Scott
Fort Scott, Kansas, 66701
Unity Hospital
Fridley, Minnesota, 55432
Cancer Research Consortium of West Michigan NCORP
Grand Rapids, Michigan, 49503
Mercy Health Saint Mary's
Grand Rapids, Michigan, 49503
Spectrum Health at Butterworth Campus
Grand Rapids, Michigan, 49503
Benefis Healthcare- Sletten Cancer Institute
Great Falls, Montana, 59405
Saint Francis Hospital
Greenville, South Carolina, 29601
Gibbs Cancer Center-Pelham
Greer, South Carolina, 29651
Hartford Hospital
Hartford, Connecticut, 06102
Smilow Cancer Hospital Care Center at Saint Francis
Hartford, Connecticut, 06105
Geisinger Medical Center-Cancer Center Hazleton
Hazleton, Pennsylvania, 18201
Saint Peter's Community Hospital
Helena, Montana, 59601
Park Ridge Hospital Breast Health Center
Hendersonville, North Carolina, 28792
M D Anderson Cancer Center
Houston, Texas, 77030
Memorial Hermann Texas Medical Center
Houston, Texas, 77030
Hutchinson Area Health Care
Hutchinson, Minnesota, 55350
Cancer Center of Kansas-Independence
Independence, Kansas, 67301
Indiana University/Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, 46202
Saint Vincent Hospital and Health Care Center
Indianapolis, Indiana, 46260
University of Iowa/Holden Comprehensive Cancer Center
Iowa City, Iowa, 52242
Allegiance Health
Jackson, Michigan, 49201
Saint Dominic-Jackson Memorial Hospital
Jackson, Mississippi, 39216
Kalispell Regional Medical Center
Kalispell, Montana, 59901
Cancer Center of Kansas-Kingman
Kingman, Kansas, 67068
Sparrow Hospital
Lansing, Michigan, 48912
Memorial Medical Center - Las Cruces
Las Cruces, New Mexico, 88011
Women's Cancer Center of Nevada
Las Vegas, Nevada, 89169
Lawrence Memorial Hospital
Lawrence, Kansas, 66044
Beebe Medical Center
Lewes, Delaware, 19958
Cancer Center of Kansas-Liberal
Liberal, Kansas, 67905
University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72205
Saint Mary Mercy Hospital
Livonia, Michigan, 48154
Kaiser Permanente Los Angeles Medical Center
Los Angeles, California, 90027
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, 90095
University of Wisconsin Hospital and Clinics
Madison, Wisconsin, 53792
Cancer Center of Kansas-Manhattan
Manhattan, Kansas, 66502
Minnesota Oncology Hematology PA-Maplewood
Maplewood, Minnesota, 55109
Saint John's Hospital - Healtheast
Maplewood, Minnesota, 55109
Marshfield Clinic
Marshfield, Wisconsin, 54449
Carle Physician Group-Mattoon/Charleston
Mattoon, Illinois, 61938
Hillcrest Hospital Cancer Center
Mayfield Heights, Ohio, 44124
Cancer Center of Kansas - McPherson
McPherson, Kansas, 67460
Lake University Ireland Cancer Center
Mentor, Ohio, 44060
Aurora Saint Luke's Medical Center
Milwaukee, Wisconsin, 53215
Froedtert and the Medical College of Wisconsin
Milwaukee, Wisconsin, 53226
Abbott-Northwestern Hospital
Minneapolis, Minnesota, 55407
Hennepin County Medical Center
Minneapolis, Minnesota, 55415
Health Partners Inc
Minneapolis, Minnesota, 55454
University of Minnesota/Masonic Cancer Center
Minneapolis, Minnesota, 55455
Saint Patrick Hospital - Community Hospital
Missoula, Montana, 59802
Memorial Medical Center
Modesto, California, 95355
Palo Alto Medical Foundation-Camino Division
Mountain View, California, 94040
Palo Alto Medical Foundation-Gynecologic Oncology
Mountain View, California, 94040
Mercy Health Mercy Campus
Muskegon, Michigan, 49444
The Hospital of Central Connecticut
New Britain, Connecticut, 06050
Tulane University Health Sciences Center
New Orleans, Louisiana, 70112
Cancer Center of Western Wisconsin
New Richmond, Wisconsin, 54017
New Ulm Medical Center
New Ulm, Minnesota, 56073
Memorial Sloan-Kettering Cancer Center
New York, New York, 10065
Christiana Gynecologic Oncology LLC
Newark, Delaware, 19713
Delaware Clinical and Laboratory Physicians PA
Newark, Delaware, 19713
Helen F Graham Cancer Center
Newark, Delaware, 19713
Medical Oncology Hematology Consultants PA
Newark, Delaware, 19713
Regional Hematology and Oncology PA
Newark, Delaware, 19713
Christiana Care Health System-Christiana Hospital
Newark, Delaware, 19718
Cancer Center of Kansas - Newton
Newton, Kansas, 67114
Lakeland Community Hospital
Niles, Michigan, 49120
Sutter Cancer Research Consortium
Novato, California, 94945
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104
Palo Alto Medical Foundation Health Care
Palo Alto, California, 94301
Paoli Memorial Hospital
Paoli, Pennsylvania, 19301
Cancer Center of Kansas - Parsons
Parsons, Kansas, 67357
Gynecologic Oncology Group of Arizona
Phoenix, Arizona, 85012
Saint Joseph's Hospital and Medical Center
Phoenix, Arizona, 85013
Mayo Clinic Hospital
Phoenix, Arizona, 85054
Saint Joseph Mercy Oakland
Pontiac, Michigan, 48341
Lake Huron Medical Center
Port Huron, Michigan, 48060
Maine Medical Center-Bramhall Campus
Portland, Maine, 04102
Kootenai Cancer Center
Post Falls, Idaho, 83854
Cancer Center of Kansas - Pratt
Pratt, Kansas, 67124
Women and Infants Hospital
Providence, Rhode Island, 02905
Spectrum Health Reed City Hospital
Reed City, Michigan, 49677
Beebe Health Campus
Rehoboth Beach, Delaware, 19971
Virginia Commonwealth University/Massey Cancer Center
Richmond, Virginia, 23298
North Memorial Medical Health Center
Robbinsdale, Minnesota, 55422
Mayo Clinic
Rochester, Minnesota, 55905
Saint John's Clinic-Rolla-Cancer and Hematology
Rolla, Missouri, 65401
Sutter Cancer Centers Radiation Oncology Services-Roseville
Roseville, California, 95661
Sutter Roseville Medical Center
Roseville, California, 95661
William Beaumont Hospital-Royal Oak
Royal Oak, Michigan, 48073
Sutter General Hospital
Sacramento, California, 95816
Saint Mary's of Michigan
Saginaw, Michigan, 48601
Lakeland Hospital
Saint Joseph, Michigan, 49085
Marie Yeager Cancer Center
Saint Joseph, Michigan, 49085
Metro Minnesota Community Oncology Research Consortium
Saint Louis Park, Minnesota, 55416
Park Nicollet Clinic - Saint Louis Park
Saint Louis Park, Minnesota, 55416
Regions Hospital
Saint Paul, Minnesota, 55101
United Hospital
Saint Paul, Minnesota, 55102
Cancer Center of Kansas - Salina
Salina, Kansas, 67401
California Pacific Medical Center-Pacific Campus
San Francisco, California, 94115
Palo Alto Medical Foundation-Santa Cruz
Santa Cruz, California, 95065
Sutter Pacific Medical Foundation
Santa Rosa, California, 95403
Memorial University Medical Center
Savannah, Georgia, 31404
Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
Savannah, Georgia, 31405
Maine Medical Center- Scarborough Campus
Scarborough, Maine, 04074
Mayo Clinic in Arizona
Scottsdale, Arizona, 85259
Saint Francis Regional Medical Center
Shakopee, Minnesota, 55379
Welch Cancer Center
Sheridan, Wyoming, 82801
Avera Cancer Institute
Sioux Falls, South Dakota, 57105
Spartanburg Medical Center
Spartanburg, South Carolina, 29303
Memorial Medical Center
Springfield, Illinois, 62781
Baystate Medical Center
Springfield, Massachusetts, 01199
Cancer Research for the Ozarks NCORP
Springfield, Missouri, 65804
Mercy Hospital Springfield
Springfield, Missouri, 65804
CoxHealth South Hospital
Springfield, Missouri, 65807
Mercy Hospital Saint Louis
St Louis, Missouri, 63141
Geisinger Medical Group
State College, Pennsylvania, 16801
Lakeview Hospital
Stillwater, Minnesota, 55082
Stony Brook University Medical Center
Stony Brook, New York, 11794
Palo Alto Medical Foundation-Sunnyvale
Sunnyvale, California, 94086
Olive View-University of California Los Angeles Medical Center
Sylmar, California, 91342
Scott and White Memorial Hospital
Temple, Texas, 76508
Munson Medical Center
Traverse City, Michigan, 49684
William Beaumont Hospital - Troy
Troy, Michigan, 48098
University of Arizona Cancer Center-North Campus
Tucson, Arizona, 85719
Oklahoma Cancer Specialists and Research Institute-Tulsa
Tulsa, Oklahoma, 74146
Carle Cancer Center
Urbana, Illinois, 61801
The Carle Foundation Hospital
Urbana, Illinois, 61801
Sutter Cancer Centers Radiation Oncology Services-Vacaville
Vacaville, California, 95687
Sutter Solano Medical Center/Cancer Center
Vallejo, California, 94589
Ridgeview Medical Center
Waconia, Minnesota, 55387
Saint John Macomb-Oakland Hospital
Warren, Michigan, 48093
Cancer Center of Kansas - Wellington
Wellington, Kansas, 67152
Aurora West Allis Medical Center
West Allis, Wisconsin, 53227
Methodist West Hospital
West Des Moines, Iowa, 50266-7700
Mercy Medical Center-West Lakes
West Des Moines, Iowa, 50266
Associates In Womens Health
Wichita, Kansas, 67208
Cancer Center of Kansas-Wichita Medical Arts Tower
Wichita, Kansas, 67208
Cancer Center of Kansas - Wichita
Wichita, Kansas, 67214
Via Christi Regional Medical Center
Wichita, Kansas, 67214
Wichita NCI Community Oncology Research Program
Wichita, Kansas, 67214
Geisinger Wyoming Valley/Henry Cancer Center
Wilkes-Barre, Pennsylvania, 18711
Rice Memorial Hospital
Willmar, Minnesota, 56201
Christiana Care Health System-Wilmington Hospital
Wilmington, Delaware, 19801
New Hanover Regional Medical Center/Zimmer Cancer Center
Wilmington, North Carolina, 28401
Cancer Center of Kansas - Winfield
Winfield, Kansas, 67156
Southeast Clinical Oncology Research (SCOR) Consortium NCORP
Winston-Salem, North Carolina, 27104
Minnesota Oncology Hematology PA-Woodbury
Woodbury, Minnesota, 55125
Lankenau Medical Center
Wynnewood, Pennsylvania, 19096
Main Line Health NCORP
Wynnewood, Pennsylvania, 19096
About this study
Official title: The LymphEdema and Gynecologic Cancer (LEG) Study: Incidence, Risk Factors, and Impact in Newly Diagnosed Patients
This clinical trial studies lymphedema after surgery in patients with endometrial cancer, cervical cancer, or vulvar cancer. Collecting information over time about how often lymphedema occurs in patients undergoing surgery and lymphadenectomy for endometrial cancer, cervical cancer, and vulvar cancer may help doctors learn more about the disease and plan the best treatment.
Read the detailed description
PRIMARY OBJECTIVES:
- To prospectively estimate the incidence of lower extremity lymphedema in patients undergoing radical surgery with a concurrent lymphadenectomy with a concurrent lymphadenectomy for a gynecologic malignancy.
II. To identify risk factors for the development of lower extremity lymphedema following radical surgery among patients with any one of the three types of gynecologic malignancy studied and to develop a corresponding predictive model.
SECONDARY OBJECTIVES:
- To identify the effect that lower extremity lymphedema has on quality of life (QOL) (as measured with Functional Assessment of Cancer Therapy - General [FACT-G] + disease specific subscale), psychological adjustment (as measured with Impact of Events Scale [IES] and Functional Assessment of Chronic Illness Therapy [FACIT] body image items) and physical disability (of lower extremity as measured with Lower Extremity Functional Scale [LEFS]) and physical function(as measured by FACT-Functional Wellbeing [FW] subscale, FACIT disease specific items \& patient-reported outcomes measurement information system [PROMIS] items) and to investigate potential protective mechanisms (FACT-Social Wellbeing [SW] subscale and patient characteristics).
II. To explore if patient self-reported symptoms (as measured with the lymphedema [LE] Symptom Measure [Cancer Lymphedema Questionnaire (GCLQ)]) are associated with the development of lymphedema in patients undergoing radical surgery for gynecologic malignancy.
TERTIARY OBJECTIVES:
- To explore the effect of moderate or severe lymphedema (primary endpoint) on QOL outcomes, as measured by the FACT-General (G) questionnaire.
OUTLINE:
Patients with vulvar cancer undergo a radical vulvectomy or hemi-vulvectomy followed immediately by an ipsilateral or bilateral inguinal-femoral lymphadenectomy. (Closed to accrual as of June 9, 2014)
Patients with cervical cancer undergo a radical hysterectomy or trachelectomy and bilateral pelvic lymphadenectomy +/- para-aortic nodal sampling via vaginal, laparoscopic, or open route.
Patients with endometrial cancer undergo a laparoscopic-assisted vaginal hysterectomy, a total laparoscopic hysterectomy, or total abdominal hysterectomy with pelvic lymphadenectomy +/- para-aortic node sampling.
Patients undergo limb measurements at baseline, weeks 4-6, and at 3, 6, 9, 12, 18, and 24 months.
- Conditions
- Lymphedema, Stage IA Cervical Cancer, Stage IA Uterine Corpus Cancer, Stage IA Vulvar Cancer, Stage IB Cervical Cancer, Stage IB Uterine Corpus Cancer
- Being tested
- Quality-of-Life Assessment, Questionnaire Administration, Study of High Risk Factors, Therapeutic Conventional Surgery, Therapeutic Laparoscopic Surgery
- Medical subject headings
- Lymphedema, Uterine Cervical Neoplasms, Vulvar Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Quality-of-Life AssessmentOther
Also called Quality of Life Assessment
Ancillary studies
Questionnaire AdministrationOther
Ancillary studies
Study of High Risk FactorsProcedure or surgery
Undergo lymphedema assessment
Therapeutic Conventional SurgeryProcedure or surgery
Undergo surgery
Therapeutic Laparoscopic SurgeryProcedure or surgery
Undergo surgery
Therapeutic LymphadenectomyProcedure or surgery
Undergo lymphadenectomy
| Study group | Role | What they receive |
|---|---|---|
| Supportive care (lymphedema assessment) | Experimental | Patients with vulvar cancer undergo a radical vulvectomy or hemi-vulvectomy followed immediately by an ipsilateral or bilateral inguinal-femoral lymphadenectomy. (Closed to accrual as of June 9, 2014)
Patients with cervical cancer undergo a radical hysterectomy or trachelectomy and bilateral pelvic lymphadenectomy +/- para-aortic nodal sampling via vaginal, laparoscopic, or open route.
Patients with endometrial cancer undergo a laparoscopic-assisted vaginal hysterectomy, a total laparoscopic hysterectomy, or total abdominal hysterectomy with pelvic lymphadenectomy +/- para-aortic node sampling.
Patients undergo limb measurements at baseline, weeks 4-6, and at 3, 6, 9, 12, 18, and 24 months. Receives: Other: Quality-of-Life Assessment; Other: Questionnaire Administration; Procedure: Study of High Risk Factors; Procedure: Therapeutic Conventional Surgery; Procedure: Therapeutic Laparoscopic Surgery; Procedure: Therapeutic Lymphadenectomy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of lymphedema, assessed through volumetric measurements using serial circumferential measurements performed from 10 cm above the heel to the inguinal crease at 10 cm intervals
A competing risks analysis will be required to estimate the cumulative incidence of lymphedema. Transition probabilities in the Markov Chain will be estimated by simple proportions, ignoring covariates, to address this primary objective. Confidence intervals for the cumulative incidence of lymphedema then will be computed using the Delta Method, utilizing the fact that the transition proportions have and asymptotic multivariate normal distribution.
Measured: Up to 24 months
Risk factors for the development of lower extremity lymphoma in patients with endometrial cancers
If risk factors are identified, a model will be developed to predict the level of risk (low, moderate, high) of lymphedema following gynecologic cancer treatment overall, and following treatment for endometrial cancer specifically. The predictive power of the models for these rates will be assessed.
Measured: Up to 24 months
Secondary outcomes (3)
Patient self-reported symptoms
Whether the patient self-reported symptoms are associated with the development of lymphedema wit be explored.
Measured: Up to 24 months
Quality of life
As measured by the FACT QOL scale, psychological adjustment as measured by the Impact of Events Subscale (IES), and FACIT body image items, physical disability as measured by the Lower Extremity Functional Scale -(LEFS) and PROs of physical health status/function (sexual), as measured by FACT-FW; FACIT \& PROMIS.
Measured: Up to 24 months
Risk factors for the development of lower extremity lymphoma in patients with cervical cancers
If risk factors are identified, a model will be developed to predict the level of risk (low, moderate, high) of lymphedema following gynecologic cancer treatment overall, and following treatment for endometrial cancer specifically. The predictive power of the models for these rates will be assessed.
Measured: Up to 24 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Aug 2009 (estimated)
- Study startJun 2012
- Primary completionApr 2015
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for LymphedemaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 1,055 participants (actual)
Sponsor and investigators
- Lead sponsor
- Gynecologic Oncology Group
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI)
- Responsible party
- Sponsor
- Investigators
- Richard Barakat, Principal investigator, NRG Oncology
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00956670
- Sponsor's protocol ID
- GOG-0244
- Other IDs
- NCI-2011-01932, CDR0000646813, GOG-0244, GOG-0244, GOG-0244, U10CA101165, UG1CA189867
- Acronym
- LEG
- Status last verified
- May 2017
- First submitted
- 8 Aug 2009
- Last updated
- 8 May 2017
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 May 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The LymphEdema and Gynecologic Cancer (LEG) Study: Incidence, Risk Factors, and Impact in Newly Diagnosed Patients
- ClinicalTrials.gov ID
- NCT00956670
- Acronym / sponsor ID
- LEG / GOG-0244
- Conditions
- Lymphedema, Stage IA Cervical Cancer, Stage IA Uterine Corpus Cancer, Stage IA Vulvar Cancer, Stage IB Cervical Cancer, Stage IB Uterine Corpus Cancer
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 1,055 participants (actual)
- Lead sponsor
- Gynecologic Oncology GroupResearch network
- Collaborators
- National Cancer Institute (NCI)
- Study start
- Jun 2012
- Primary completion
- Apr 2015 (actual)
- First posted
- 11 Aug 2009 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This clinical trial studies lymphedema after surgery in patients with endometrial cancer, cervical cancer, or vulvar cancer. Collecting information over time about how often lymphedema occurs in patients undergoing surgery and lymphadenectomy for endometrial cancer, cervical cancer, and vulvar cancer may help doctors learn more about the disease and plan the best treatment.
Detailed description
PRIMARY OBJECTIVES:
- To prospectively estimate the incidence of lower extremity lymphedema in patients undergoing radical surgery with a concurrent lymphadenectomy with a concurrent lymphadenectomy for a gynecologic malignancy.
II. To identify risk factors for the development of lower extremity lymphedema following radical surgery among patients with any one of the three types of gynecologic malignancy studied and to develop a corresponding predictive model.
SECONDARY OBJECTIVES:
- To identify the effect that lower extremity lymphedema has on quality of life (QOL) (as measured with Functional Assessment of Cancer Therapy - General [FACT-G] + disease specific subscale), psychological adjustment (as measured with Impact of Events Scale [IES] and Functional Assessment of Chronic Illness Therapy [FACIT] body image items) and physical disability (of lower extremity as measured with Lower Extremity Functional Scale [LEFS]) and physical function(as measured by FACT-Functional Wellbeing [FW] subscale, FACIT disease specific items \& patient-reported outcomes measurement information system [PROMIS] items) and to investigate potential protective mechanisms (FACT-Social Wellbeing [SW] subscale and patient characteristics).
II. To explore if patient self-reported symptoms (as measured with the lymphedema [LE] Symptom Measure [Cancer Lymphedema Questionnaire (GCLQ)]) are associated with the development of lymphedema in patients undergoing radical surgery for gynecologic malignancy.
TERTIARY OBJECTIVES:
- To explore the effect of moderate or severe lymphedema (primary endpoint) on QOL outcomes, as measured by the FACT-General (G) questionnaire.
OUTLINE:
Patients with vulvar cancer undergo a radical vulvectomy or hemi-vulvectomy followed immediately by an ipsilateral or bilateral inguinal-femoral lymphadenectomy. (Closed to accrual as of June 9, 2014)
Patients with cervical cancer undergo a radical hysterectomy or trachelectomy and bilateral pelvic lymphadenectomy +/- para-aortic nodal sampling via vaginal, laparoscopic, or open route.
Patients with endometrial cancer undergo a laparoscopic-assisted vaginal hysterectomy, a total laparoscopic hysterectomy, or total abdominal hysterectomy with pelvic lymphadenectomy +/- para-aortic node sampling.
Patients undergo limb measurements at baseline, weeks 4-6, and at 3, 6, 9, 12, 18, and 24 months.
Study design
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Supportive care (lymphedema assessment) | Experimental | Other: Quality-of-Life Assessment, Other: Questionnaire Administration, Procedure: Study of High Risk Factors, Procedure: Therapeutic Conventional Surgery, Procedure: Therapeutic Laparoscopic Surgery, Procedure: Therapeutic LymphadenectomyPatients with vulvar cancer undergo a radical vulvectomy or hemi-vulvectomy followed immediately by an ipsilateral or bilateral inguinal-femoral lymphadenectomy. (Closed to accrual as of June 9, 2014) Patients with cervical cancer undergo a radical hysterectomy or trachelectomy and bilateral pelvic lymphadenectomy +/- para-aortic nodal sampling via vaginal, laparoscopic, or open route. Patients with endometrial cancer undergo a laparoscopic-assisted vaginal hysterectomy, a total laparoscopic hysterectomy, or total abdominal hysterectomy with pelvic lymphadenectomy +/- para-aortic node sampling. Patients undergo limb measurements at baseline, weeks 4-6, and at 3, 6, 9, 12, 18, and 24 months. |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Patients will be registered into three distinct groupings, and each group will be analyzed as a separate study:
- Patients must have signed an approved informed consent and authorization permitting release of personal health information
- Patients must have a serum albumin level of >= 3.0 within 14 days of entry
- Surgery must occur within 5 business days before study entry or within eight weeks after study entry
Key exclusion criteria (12 listed)
- Patients with any prior clinical history of lower extremity lymphedema
- Patients who have a history of congestive heart failure, chronic renal disease, or chronic liver disease
- Patients with a prior history of chronic lower extremity swelling
- Patients with a Gynecologic Oncology Group (GOG) performance grade of 3 or 4
- Patients with a history of other invasive malignancies if their previous cancer treatment included any of the surgical procedures
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Quality-of-Life AssessmentAlso: Quality of Life AssessmentAncillary studies | Other | Supportive care (lymphedema assessment) |
| Questionnaire AdministrationAncillary studies | Other | Supportive care (lymphedema assessment) |
| Study of High Risk FactorsUndergo lymphedema assessment | Procedure or surgery | Supportive care (lymphedema assessment) |
| Therapeutic Conventional SurgeryUndergo surgery | Procedure or surgery | Supportive care (lymphedema assessment) |
| Therapeutic Laparoscopic SurgeryUndergo surgery | Procedure or surgery | Supportive care (lymphedema assessment) |
| Therapeutic LymphadenectomyUndergo lymphadenectomy | Procedure or surgery | Supportive care (lymphedema assessment) |
Primary outcome
Incidence of lymphedema, assessed through volumetric measurements using serial circumferential measurements performed from 10 cm above the heel to the inguinal crease at 10 cm intervals
Time frame: Up to 24 months
A competing risks analysis will be required to estimate the cumulative incidence of lymphedema. Transition probabilities in the Markov Chain will be estimated by simple proportions, ignoring covariates, to address this primary objective. Confidence intervals for the cumulative incidence of lymphedema then will be computed using the Delta Method, utilizing the fact that the transition proportions have and asymptotic multivariate normal distribution.
Risk factors for the development of lower extremity lymphoma in patients with endometrial cancers
Time frame: Up to 24 months
If risk factors are identified, a model will be developed to predict the level of risk (low, moderate, high) of lymphedema following gynecologic cancer treatment overall, and following treatment for endometrial cancer specifically. The predictive power of the models for these rates will be assessed.
3 secondary outcomes
Patient self-reported symptoms
Time frame: Up to 24 months
Quality of life
Time frame: Up to 24 months
Risk factors for the development of lower extremity lymphoma in patients with cervical cancers
Time frame: Up to 24 months
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 May 2017.
Related trials for Lymphedema
Not yet recruitingObservational study
Comparison of Reliability, Time Cost, and Participant Comfort of Lymphedema Assessments in Upper Extremity
Lymphedema, Upper Extremity Lymphedema
Enrolling by invitation
Comparison of the Effects of Kinesio Taping and Compression Bandaging on Edema, Range of Motion, Upper Extremity Function, and Grip Strength in Patients With Breast Cancer-Related Lymphedema
Lymphedema, Lymphedema Arm
RecruitingObservational study
A Post-market, Real-world Experience: Expanding Access to Care by Incorporating the Symani® Surgical System and Enabling Surgeons
Open Surgery, Lymphedema
Not yet recruiting
Agentic AI App and Home Bioimpedance Monitoring for Endocrine Therapy Adherence and Lymphedema in Breast Cancer Survivors
Breast Neoplasm Malignant Primary, Lymphedema Arm
Active, not recruiting
The Effectiveness of Lymphatic Bypass Supermicrosurgery
Breast Cancer Related Lymphedema, Lymphedema Arm
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Richard Barakat principal investigator
NRG Oncology
213 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Quality-of-Life Assessment, Questionnaire Administration and Study of High Risk Factors in people with Lymphedema and Stage IA Cervical Cancer, run by Gynecologic Oncology Group at 213 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 8 May 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 213 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of lymphedema, assessed through volumetric measurements using serial circumferential measurements performed from 10 cm above the heel to the inguinal crease at 10 cm intervals (time frame: Up to 24 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 May 2017.